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Purpose: To evaluate a multi-group-specific sequence-based typing (SBT) method 
for resolving ambiguous results from human leukocyte antigen (HLA) genotyping. 
Materials and Methods: A total of 50 samples that showed ambiguous genotypes 
for at least two HLA loci from HLA-A, -B, -C and -DRB1 by the conventional SBT 
assay were evaluated using a new SBT test, the AVITA plus assay. The most likely 
HLA genotypes for the respective samples considering allele frequencies in Korean 
were concordant between the AVITA and conventional SBT assays. Results: An av-
erage of 3.3 loci among the HLA-A, -B, -C and -DRB1 loci per sample gave results 
with two or more possible allele combinations with the conventional SBT, and 48 
(96.0%) out of 50 showed reduced numbers of possible genotypes for at least one 
HLA locus with the AVITA. A total of 41, 43, 42, and 38 cases among the 50 samples 
showed ambiguous results for HLA-A, -B, -C, and -DRB1 typing by the conventional 
SBT, respectively. The average numbers of possible allele combinations for the re-
spective four HLA loci were 8.2, 6.7, 5.9, and 3.2, and they were reduced to 1.5, 2.2, 
4.4, and 1.8, respectively, by the AVITA. Ambiguity was resolved by the AVITA in 
33 (80.5%), 31 (72.1%), 17 (40.5%) and 28 (73.7%) samples among the ambiguous 
cases from the conventional SBT for HLA-A, -B, -C, and -DRB1 typing, respectively. 
Conclusion: The multi-group-specific SBT method considerably reduced the num-
ber of ambiguous results, and thus may be useful for accurate HLA typing in clinical 
laboratories.
Key Words:   Human leukocyte antigen, sequence-based typing, ambiguity, high 
resolution, multi-group-specific PCR
INTRODUCTION
The introduction of human leukocyte antigen (HLA) genotyping, particularly by 
high-resolution sequence-based typing (SBT), has significantly advanced patient’s 
survival after hematopoietic stem cell transplantation.1-3 However, ‘ambiguous’ al-
lele combinations by the SBT are often encountered in the determination of HLA 
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donors.8 The failure to identify an HLA null allele, which 
may not actually stimulate allogenic T cells and trigger 
graft versus host disease, may mislead into determining as 
an HLA mismatched case in the stem cell transplantation 
setting, although prevalence of HLA null alleles may be 
around 0.3%.9
Post hoc sequence-specific primer or sequence-specific 
oligonucleotide probe assay is necessary to resolve the ambi-
guity in some instances. The ambiguity in an SBT may also 
be resolved by a group-specific polymerase chain reaction 
(PCR) for the separated amplification of a single haplotype 
or by an SBT after haplotype-specific DNA extraction.10,11 
Another approach to resolve the ambiguity from the SBT is 
to utilize the heterozygous ambiguity resolving primers 
(HARPs) for the sequencing step of an SBT. The AlleleSE-
QR® HARPs (Celera Co., Alameda, CA, USA) are designed 
to sequence single allele from the mixture of amplified PCR 
products, when the correct types of HARPs are chosen. In a 
recent report, 95%, 86%, and 60% of ambiguous results in 
HLA-A, -B, and -DRB1 typing, respectively, could be re-
solved using HARPs.12 In addition, recent advances in se-
quencing methodologies including massive parallel pyrose-
quencing would be helpful in exact HLA genotyping and 
resolving the ambiguity, but the next-generation sequencing 
methods are still expensive to perform in clinical laborato-
ries and are also labor-intensive.13-17
Recently, a new commercial SBT assay was developed in 
order to resolve the ambiguity in the high-resolution HLA 
typing by employing multi-group specific sequencing to re-
duce cis-trans isomerism as well as increasing the number of 
sequenced exons in some instances. In this study, we evalu-
ated this new SBT assay for its usefulness in reducing am-
biguous HLA typing by comparing the results of this new 




Between February 2010 and January 2012, 50 DNA prepa-
rations that showed ambiguous allele combinations for at 
least two HLA loci among HLA-A, -B, -C, and -DRB1 in 
SBT with AlleleSEQR® HLA PCR kits (Celera Co., Alam-
eda, CA, USA) were consecutively collected from 50 unre-
lated Korean individuals with written consents. DNA from 
whole blood samples was extracted using a QuickGene-
Mini 80 nucleic acid isolation instrument with the Quick-
genotypes in clinical laboratories.
The HLA loci are the most polymorphic genes in human, 
and are characterized by extensive gene duplication and re-
combination.4 The homology among HLA genes as well as 
the extensive polymorphism in exons encoding the peptide-
binding domains can obscure exact identification of an in-
dividual’s HLA alleles. When HLA genotyping is based on 
specific international immunogenetics (IMGT)/HLA data-
base releases, genotyping systems that can assess fewer 
polymorphisms will generate more ambiguous HLA geno-
type data. In other words, ambiguous genotyping results 
may arise when the polymorphisms that distinguish be-
tween highly homologous alleles are located outside of re-
gions assessed by a SBT system. However, it is not consid-
ered cost-effective to identify all of the polymorphisms that 
can distinguish closely related alleles, and ambiguities in al-
leles with identical antigen recognition sites are usually pre-
sumed to be clinically irrelevant.5 In these circumstances, 
HLA genotyping results can be ambiguous in that the re-
sults for a given sample can have many cis/trans combina-
tions of polymorphic sites and may be consistent with more 
than two potential alleles at a given locus (cis/trans or phase 
ambiguity). A previous study reported that 41% of HLA-A 
and 24% of HLA-B allele typing showed phase ambiguity 
by SBT when exons 2 and 3 of the HLA-A and -B loci were 
analyzed.6
Currently, a total of 10533 HLA alleles are registered in 
the IMGT/HLA database release 3.15.0 (January 2014).4 As 
more HLA alleles are identified, more ambiguity would 
arise from SBT, and the potential for ambiguous results in-
creases as advanced typing methodology identifies more 
polymorphisms outside the conventional targets of SBT as-
says. In addition, a genotype that is unambiguous, based on 
one past IMGT/HLA database release, may become ambig-
uous in the context of later releases due to the newly regis-
tered homologous alleles. In these contexts, distinctive allele 
and haplotype frequencies in a certain ethnic or population 
group depending on linkage disequilibrium as well as the fre-
quencies of common alleles are usually referenced, and the 
most common allele combination is often reported when 
SBT gives ambiguous HLA genotypes.7 However, this ap-
proach is problematic when an individual actually has rare 
HLA alleles that are highly homologous with common al-
leles, leading to incorrect interpretation of genotyping results. 
In addition, ambiguities that include unsequenced regions de-
fining null or low expression alleles could be clinically signif-
icant in some instances including searching for unrelated 
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results were analyzed using BIOWITHUS SBT analyzer 
software ver. 2.7.4 (Biowithus Inc.).
Data analysis
The most probable HLA-A, -B, -C, and -DRB1 genotypes 
for the respective samples were determined based on the 
previous reports for allele frequencies in Koreans.18,19 Based 
on the reported HLA allele frequencies,18,20 expected geno-
type frequency in Korea and United States was calculated 
by the Hardy-Weinberg equation. All sequenced data from 
the two SBT assays were analyzed based on the IMGT/
HLA database release 3.9.0 (July 2012). Ambiguous HLA 
alleles that had identical nucleotide sequences across the 
exons encoding the peptide-binding domains (exon 2 and 3 
for HLA class I and exon 2 only for HLA class II alleles) 
were designated to the ‘G’ group and regarded as a single 
allele type. Alleles within the same G code were referred to 
as the current G group designation, which is available from 




Overall agreement between the two SBT assays
When considering the allele frequencies in Koreans, the 
most common HLA-A, -B, -C, and -DRB1 genotypes for 
the respective 50 specimens, determined by the AVITA plus 
SBT kits, were all concordant with those from the conven-
tional SBT assay.
Cases with ambiguous results
HLA genotypes analyzed in this study were determined ac-
Gene DNA whole blood kit S (FUJIFILM Co., Tokyo, Ja-
pan), and stored at -70°C for later uses.
Conventional SBT assay
PCR and sequencing were performed for exon 2 of the HLA-
DRB1 gene as well as exons 2 to 4 of the HLA-A, -B, and -C 
genes using AlleleSEQR® HLA-A, -B, -C, and -DRB1 PCR 
kits (Celera Co.) according to the manufacturer’s instruc-
tions. Condon86 HARPs were also used in sequencing PCR 
for exon 2 of the HLA-DRB1 locus. The resulting nucleic 
acid sequences were read by an ABI 3100 DNA analyzer 
(Applied Biosystems, Foster City, CA, USA). All sequenced 
results were analyzed using AssignTM SBT software ver. 
3.5.1.45 (Conexio Genomics Pty Ltd., Fremantle, Australia).
Multi-group-specific SBT assay
SBT was performed for all 50 samples again using AVI-
TATM plus HLA SBT kits (Biowithus Inc., Seoul, Korea) 
according to the manufacturer’s instructions. The same 
DNA preparations that had been used for the AlleleSEQR® 
SBT assays were tested. The AVITA plus assay utilizes 2 or 
4 PCR reaction tubes for multi-group-specific primer am-
plifications of HLA genes (2, 4, 2, and 4 tubes for the am-
plification of HLA-A, -B, -C, and -DRB1 loci, respectively). 
For example, different groups of HLA-B alleles are sepa-
rately amplified in 4 different tubes in which different prim-
er sets for different HLA-B groups are utilized for PCR am-
plification (Table 1). With the PCR products from each 
tube, sequencing PCR was performed for exons 1 to 5 of 
the HLA-A, and -C loci, exons 2 to 4 of the HLA-B locus, 
and for exon 2 of the HLA-DRB1 locus based on the Sanger 
sequencing principle, and then, nucleic acid sequences 
were read by an ABI 3730 DNA analyzer. The sequenced 
Table 1. Allocation of HLA Alleles for the Multi-Group-Specific Amplifications
Locus PCR tube Amplified region Designated alleles for the amplification Sequenced region
HLA-A
1 5’ UTR to intron 5 A*02, 25, 26, 29, 31, 32, 33, 34, 66, 68, 69, 74 Exons 1 to 5
2 5’ UTR to intron 5 A*01, 03, 11, 23, 24, 30, 36,43, 80 Exons 1 to 5
HLA-B
1 Intron 1 to intron 4 B*07, 08, 14, 38, 39, 42, 48, 67,81 Exons 2 to 4
2 Intron 1 to intron 4 B*35, 51, 52, 53, 58, 78 Exons 2 to 4
3 Intron 1 to intron 4 B*27, 40, 41, 44, 47, 83 Exons 2 to 4
4 Intron 1 to intron 4 B*13, 15, 18, 37, 45, 46, 49, 50, 54, 55, 56, 57, 59, 73, 82 Exons 2 to 4
HLA-C
1 5’ UTR to intron 5 C*01, 03, 04, 07, 14, 17, 18 Exons 1 to 5
2 5’ UTR to intron 5 C*02, 05, 06, 08, 12, 15, 16 Exons 1 to 5
HLA-DRB1
1 Exon 2 DRB1*01, 10, 15, 16 Exon 2
2 Exon 2 DRB1*03, 08, 11, 12, 13, 14 Exon 2
3 Exon 2 DRB1*04, 07, 09 Exon 2
4 Exon 2 Alleles with GTG at codon 86 Exon 2
UTR, untranslated region; HLA, human leukocyte antigen.
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plus assay for HLA-A, -B, -C, and -DRB1 typing are summa-
rized in Table 3-6, respectively. HLA-A*24:02:01G/*26: 
01:01, *02:01:01G/*11:01:01, and *02:01:01G/*24:02:01G 
accounted for 6 (14.6%), 5 (12.2%), and 5 (12.2%) cases 
with 10, 14, and 15 possible allele combinations, respec-
tively, and the ambiguities were resolved in those cases by 
the AVITA plus assay. The average number of possible al-
lele combinations with the conventional SBT was 8.22 for 
the 41 samples with ambiguity in the HLA-A locus, and the 
number was reduced to 1.54 with the AVITA plus test (Ta-
ble 3). HLA-B*15:01:01G/*51:01:01 was the most fre-
quent ambiguous allele type (5 cases, 11.6%) with 16 possi-
ble allele combinations, and ambiguities were also resolved 
in those cases with the AVITA plus assay. The average num-
ber of possible allele combinations by the conventional SBT 
was 6.65 for the 42 samples with ambiguity in the HLA-B 
locus, and the number was reduced to 2.23 with the AVITA 
plus test (Table 4). In the HLA-C genotyping, 17 (40.5%) 
out of 42 cases with ambiguous allele combinations by the 
conventional SBT showed a reduction in the numbers of 
possible allele combinations. The average number of possi-
ble genotypes with the conventional SBT was 5.86 in the 
42 samples, and the number was reduced to 4.38 with the 
AVITA plus test (Table 5). Ambiguity in the HLA-DRB1 
typing was also reduced or resolved with the AVITA plus 
SBT in 28 (73.7%) of the 38 cases that had ambiguous re-
sults with the conventional SBT assay, and the average 
number of possible genotypes with the AVITA plus assay in 
the 38 samples was reduced from 3.16 to 1.79 (Table 6).
DISCUSSION
The advances in HLA typing methods from serological 
tools using specific antibodies to molecular techniques are 
cording to the IMGT/HLA database release 3.9.0. The ambi-
guity in genotyped results and the total number of ambiguous 
allele combinations for each HLA locus by the SBT assays 
would change, depending on the version of the IMGT/ HLA 
database release.
The numbers of cases with ambiguous results by the two 
SBT assays are summarized in Table 2. Among the four 
HLA-A, -B, -C, and -DRB1 loci for the 50 samples, an aver-
age of 3.28 loci per sample showed ambiguous results with 
the conventional SBT assay. The average numbers of possi-
ble allele combinations for HLA-A, -B, -C, and -DRB1 in 
the 50 samples were 6.92, 5.86, 5.08, and 2.64, respective-
ly, with the conventional SBT, and the numbers were re-
duced to 1.44, 2.06, 3.84, and 1.60, respectively, with AVI-
TA plus SBT. In addition, 48 (96.0%) samples among the 50 
showed a reduction in the numbers of ambiguous allele 
combinations for at least one HLA locus. A total of 41, 43, 
42, and 38 cases showed ambiguous results for HLA-A, -B, 
-C, and -DRB1 typing, respectively, with the conventional 
SBT, and for a total of 33 (80.5%), 31 (72.1%), 17 (40.5%), 
and 28 (73.7%) cases among them, ambiguity was resolved 
by the AVITA plus kits.
Based on the allele frequencies from the previous report,18 
ambiguous allele combinations assessed in this study ac-
counted for 50.6%, 14.9%, 41.0%, and 16.9% among all 
possible genotypes in Korean for HLA-A, -B, -C, and -DRB1 
loci, respectively. The AVITA plus assay would be expected 
to resolve ambiguity for 34.4%, 11.7%, 15.5%, and 13.9% 
of the possible genotypes for HLA-A, -B, -C, and -DRB1 
loci in the same population, respectively (Table 3-6).
Reduction in the number of ambiguous combinations 
according to HLA loci
The detailed genotypes and the numbers of possible allele 
combinations with both the conventional SBT and AVITA 
Table 2. Reduction of Ambiguous HLA Allele* Combinations with the AVITA Plus SBT Assay
Locus
N (%) of cases with ambiguity % reduction in N of cases  
with ambiguityConventional SBT AVITA plus
HLA-A 41 (82.0)   8 (16.0) 80.5%
HLA-B 43 (86.0) 12 (24.0) 72.1%
HLA-C 42 (84.0) 25 (50.0) 40.5%
HLA-DRB1 38 (76.0) 10 (20.0) 73.7%
Any of the above†   50 (100.0) 36 (72.0) 28.0%
SBT, sequence-based typing; HLA, human leukocyte antigen; IMGT, international immunogenetics.
*HLA genotypes were determined based on the IMGT/HLA database release 3.9.0. The occurrence of ambiguous genotyping results and the number of 
ambiguous allele combinations by an SBT assay for an individual may change according to the version of the IMGT/HLA database release.
†Average number of loci with ambiguity per sample was 3.28 in the 50 specimens, and this was reduced to 1.22 (61.8% reduction) with the AVITA plus as-
say. A total of 48 (96.0%) cases among the 50 specimens showed reduction in the number of ambiguous allele combinations for any of the four HLA loci.
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tively. The AVITA plus assay would also be expected to re-
solve ambiguity in more than 12% to 34% of all possible 
genotypes for each HLA locus in Korean population, when 
considered that there would be other HLA genotypes which 
were not included in our study.
Considering each HLA locus, the ambiguous results were 
resolved or the numbers of possible allele combinations were 
reduced mostly in the HLA-A typing, followed by HLA-
DRB1 and -B. In our data, A*24:02:01G/A*26:01:01, 
A*02:01:01G/A*11:01:01, and A*02:01:01G/A*24:02:01G 
were common genotypes with ambiguities that were re-
solved by the AVITA plus assay. This assay uses two sepa-
rate tubes for the amplification of the HLA-A locus, i.e., 
A*02, 25, 26, 29, 31, 32, 33, 34, 66, 68, 69, and 74 groups 
were designated to be amplified in a PCR tube containing 
specific primer sets for the respective HLA-A allele groups, 
good examples of how technology has enhanced clinical 
practice and patient care. In this study, we performed high-
resolution SBT using a new commercial AVITA plus assay, 
which was previously developed in order to resolve com-
mon types of ambiguous allele combinations that often arise 
from the conventional SBT. This new assay utilizes a group-
specific PCR principle for single allele separation. A previ-
ous study reported a similar strategy for HLA-A typing with 
10 primer sets for exons 2 and 3,10 and the AVITA plus as-
say expanded this strategy to HLA-B, -C, and -DRB1 typing 
with the inclusion of exons 1, 4, 5 of HLA-A and -C loci 
and exon 4 of HLA-B locus in the amplified regions. Con-
sequently, the AVITA plus SBT assay resolved the ambigui-
ty in 80.5%, 72.1%, 40.5%, and 73.7% of cases, which had 
showed two or more possible allele combinations with a 
conventional SBT for HLA-A, -B, -C, and -DRB1, respec-
Table 3. Reduction of Ambiguous Allele* Combinations with the AVITA Plus Assay for HLA-A locus
Changes in 
  ambiguity
Most probable type 
among ambiguous allele 
combinations













in US African 
American†













A*01:01:01G/A*02:01:01G   1 (2.4)   0.69 10.20 0.55 10 1 90.0%
A*02:01:01G/A*03:01:01G   2 (4.9)   0.53   8.27 1.04 12 1 91.7%
A*02:01:01G/A*11:01:01   5 (12.2)   3.14   3.30 0.17 14 1 92.9%
A*02:01:01G/A*24:02:01G   5 (12.2)   7.56   5.12 0.30 15 1 93.3%
A*02:06:01/A*11:01:01   2 (4.9)   1.81   0.02 0.00   7 1 85.7%
A*02:06:01/A*24:02:01G   2 (4.9)   4.35   0.04 0.00   9 1 88.9%
A*02:07:01/A*24:02:01G   1 (2.4)   1.60   0.00 0.00   4 1 75.0%
A*03:01:01G/A*26:01:01   1 (2.4)   0.12   0.84 0.27   6 1 83.3%
A*11:01:01/A*31:01:02   1 (2.4)   0.86   0.27 0.03   2 1 50.0%
A*11:01:01/A*33:03:01   2 (4.9)   2.93   0.02 0.16   3 1 66.7%
A*24:02:01G/A*26:01:01   6 (14.6)   1.74   0.52 0.08 10 1 90.0%
A*24:02:01G/A*31:01:02   2 (4.9)   2.06   0.41 0.06   6 1 83.3%
A*24:02:01G/A*33:03:01   3 (7.3)   7.05   0.02 0.27   2 1 50.0%
Subtotal/average 33 (80.5) 34.43 29.03 2.93   9.30 1.00 89.3%
Unchanged
A*02:01:01G/A*29:01:01G   1 (2.4)   0.17   0.11 0.01   3 3   0.0%
A*02:01:01G/A*31:01:02   1 (2.4)   1.49   1.40 0.13   4 4   0.0%
A*02:01:01G/A*33:03:01   1 (2.4)   5.08   0.08 0.62   4 4   0.0%
A*02:06:01/A*32:01:01   1 (2.4)   0.11   0.01 0.00   4 4   0.0%
A*02:06:01/A*33:03:01   1 (2.4)   2.93   0.00 0.00   2 2   0.0%
A*02:07:01/A*31:01:02   1 (2.4)   0.32   0.00 0.00   2 2   0.0%
A*11:01:01/A*24:02:01G   1 (2.4)   4.35   0.97 0.08   8 8   0.0%
A*24:02:01G/A*30:01:01   1 (2.4)   1.74   0.23 0.39   3 3   0.0%
Subtotal/average   8 (19.5) 16.18   2.82 1.24   3.75 3.75   0.0%
Total/average 41 (100.0) 50.61 31.85 4.18   8.22 1.54 81.3%
SBT, sequence-based typing; HLA, human leukocyte antigen; IMGT, international immunogenetics.
*HLA genotypes were determined based on the IMGT/HLA database release 3.9.0. The occurrence of ambiguous genotyping results and the number of 
ambiguous allele combinations by an SBT assay for an individual may change according to the version of the IMGT/HLA database release.
†Expected genotype frequency was calculated by the Hardy-Weinberg equation with previously reported allele frequencies in Korean and US populations.18,20
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been amplified in the same PCR tube, hindering the resolu-
tion of the ambiguity. In the same manner, the alleles, for 
which the ambiguity was resolved by the AVITA plus as-
say, were amplified in different PCR tubes for HLA-B, -C, 
and -DRB1 typing. The increase of the number of reaction 
tubes for more subdivided allele group-specific PCR of 
HLA can resolve the ambiguity in more cases, but would be 
labor-intensive and not cost-effective. Therefore, determin-
while A*01, 03, 11, 23, 24, 30, 36, 43, and 80 groups were 
amplified in another tube (Table 1). Therefore, ambiguous 
typing that had arisen from the above-mentioned combina-
tions could be resolved, because the A*24 or A*11 groups 
were amplified in a reaction tube that was different from 
one used for the amplification of A*02 or A*26. However, 
in cases where ambiguities were not resolved by the AVITA 
plus assay, all possible HLA-A allele combinations had 
Table 4. Reduction of Ambiguous Allele* Combinations with the AVITA Plus Assay for HLA-B locus
Changes in   
  ambiguity
Most probable type 
among ambiguous allele 
combinations













in US African 
American†












B*07:02:01G/B*13:02:01 1 (2.3)  0.31 0.72 0.15  5  1 80.0%
B*07:02:01G/B*35:03:01 1 (2.3)  0.03 0.42 0.03  7  1 85.7%
B*07:02:01G/B*40:06:01G 2 (4.7)  0.26 0.00 0.00  3  1 66.7%
B*07:02:01G/B*44:03:01 1 (2.3)  0.66 1.43 0.76 13  1 92.3%
B*07:02:01G/B*54:01:01 2 (4.7)  0.44 0.00 0.00  6  1 83.3%
B*13:02:01/B*40:01:01G 1 (2.3)  0.33 0.28 0.03  3  1 66.7%
B*13:02:01/B*51:01:01 1 (2.3)  0.78 0.22 0.04  3  1 66.7%
B*15:01:01G/B*35:01:01G 2 (4.7)  1.09 0.74 0.13 11  2 81.8%
B*15:01:01G/B*40:01:01G 3 (7.0)  0.81 0.72 0.03  9  2 77.8%
B*15:01:01G/B*40:02:01 1 (2.3)  0.96 0.13 0.01  6  1 83.3%
B*15:01:01G/B*44:02:01G 1 (2.3)  0.24 1.20 0.04  6  2 66.7%
B*15:01:01G/B*48:01:01 2 (4.7)  0.64 0.01 0.00  4  1 75.0%
B*15:01:01G/B*51:01:01  5 (11.6)  1.92 0.57 0.04 16  1 93.8%
B*15:11:01/B*44:02:01G 1 (2.3)  0.05 0.00 0.00  2  1 50.0%
B*15:11:01/B*51:01:01 1 (2.3)  0.43 0.00 0.00  2  1 50.0%
B*27:05:02G/B*37:01:01 1 (2.3)  0.09 0.08 0.01  2  1 50.0%
B*35:01:01G/B*40:02:01 1 (2.3)  0.59 0.11 0.05  8  1 87.5%
B*35:01:01G/B*44:03:01 1 (2.3)  0.94 0.58 0.71  5  1 80.0%
B*39:01:01G/B*51:01:01 1 (2.3)  0.24 0.08 0.02  3  1 66.7%
B*40:01:01G/B*58:01:01 1 (2.3)  0.49 0.05 0.09  2  1 50.0%
B*44:03:01/B*52:01:01G 1 (2.3)  0.37 0.09 0.16  5  1 80.0%
Subtotal/average 31 (72.1) 11.69 7.46 2.29       7.32       1.19 83.7%
Unchanged
B*15:01:01G/B*56:01:01 2 (4.7)  0.04 0.06 0.00  3  3   0.0%
B*15:02:01/B*54:01:01 1 (2.3)  0.04 0.00 0.00  2  2   0.0%
B*15:18:01/B*55:02:01 1 (2.3)  0.05 0.00 0.00  4  4   0.0%
B*27:05:02G/B*44:02:01G 1 (2.3)  0.09 0.57 0.03  4  4   0.0%
B*35:01:01G/B*46:01:01 1 (2.3)  0.59 0.00 0.00  2  2   0.0%
B*35:01:01G/B*51:01:01 3 (7.0)  1.18 0.48 0.26 10 10   0.0%
B*35:01:01G/B*51:02:01 1 (2.3)  0.10 0.00 0.01  3  3   0.0%
B*40:02:01/B*44:03:02 1 (2.3)  0.83 0.10 0.04  4  4   0.0%
B*52:01:01G/B*58:01:01 1 (2.3)  0.26 0.01 0.10  4  4   0.0%
Subtotal/average 12 (27.9)  3.19 1.23 0.44       4.92       4.92   0.0%
Total/average   43 (100.0) 14.88 8.69 2.73       6.65       2.23 66.4%
SBT, sequence-based typing; HLA, human leukocyte antigen; IMGT, international immunogenetics.
*HLA genotypes were determined based on the IMGT/HLA database release 3.9.0. The occurrence of ambiguous genotyping results and the number of 
ambiguous allele combinations by an SBT assay for an individual may change according to the version of the IMGT/HLA database release.
†Expected genotype frequency was calculated by the Hardy-Weinberg equation with previously reported allele frequencies in Korean and US populations.18,20
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ventional SBT.
The AVITA plus assay and the HARPs technique have a 
common advantage in that preliminary or additional testing 
phases are usually not necessary to resolve the ambiguity, 
and both methods seem to be effective in resolving the am-
biguous genotyping. However, the HARPs method requires 
ing adequate numbers of reaction tubes for group-specific 
PCRs of the respective HLA loci is the key to cost-effec-
tiveness, and the AVITA plus SBT assay may be efficient 
and cost-effective in reducing the ambiguity of HLA typing 
with the use of 2 or 4 reaction tubes per HLA locus. Actual-
ly, the cost for the AVITA assay is similar to that of the con-
Table 5. Reduction of Ambiguous Allele* Combinations with the AVITA Plus Assay for HLA-C locus
Changes in 
  ambiguity
Most probable type among 
ambiguous allele 
combinations













in US African 
American†













C*01:02:01G/C*05:01:01G 1 (2.4)   0.52  0.54  0.06  5   1 80.0%
C*01:02:01G/C*06:02:01G 1 (2.4)   1.98  0.53  0.15  6   1 80.0%
C*01:02:01G/C*08:01:01G 1 (2.4)   2.96  0.00  0.00  2  1 50.0%
C*01:02:01G/C*12:02:02 1 (2.4)   0.80  0.05  0.00  2   1 50.0%
C*03:03:01G/C*05:01:01G 1 (2.4)   0.33  1.00  0.09  7   1 85.7%
C*03:03:01G/C*15:02:01 1 (2.4)   0.74  0.20  0.01  6   1 83.3%
C*03:04:01G/C*06:02:01G 1 (2.4)   1.13  1.48  0.95  7   1 85.7%
C*03:04:01G/C*08:01:01G 1 (2.4)   1.68  0.00  0.01  3   1 66.7%
C*04:01:01G/C*08:01:01G 1 (2.4)   1.02  0.00  0.04  3   1 66.7%
C*05:01:01G/C*07:04:01G 1 (2.4)   0.02  0.21  0.07  4   1 75.0%
C*06:02:01G/C*07:02:01G 1 (2.4)   0.82  2.73  1.22  5   1 80.0%
C*06:02:01G/C*14:02:01 1 (2.4)   0.90  0.19  0.23  6   1 83.3%
C*07:02:01G/C*08:01:01G 3 (7.1)   1.22  0.00  0.01  5   1 80.0%
C*07:02:01G/C*12:03:01G 1 (2.4)   0.04  1.47  0.24  6   1 83.3%
C*08:01:01G/C*14:02:01 1 (2.4)   1.34  0.00  0.00  2   1 50.0%
Subtotal/average 17 (40.5) 15.51  8.39  3.09       4.65        1.00 78.5%
Unchanged
C*01:02:01G/C*03:03:01G 1 (2.4)   3.79  0.31  0.02  6   6   0.0%
C*01:02:01G/C*03:04:01G 1 (2.4)   3.45  0.46  0.09  9   9   0.0%
C*01:02:01G/C*04:01:01G 1 (2.4)   2.09  0.61  0.32  6   6   0.0%
C*01:02:01G/C*07:01:01G 1 (2.4)   1.15  0.99  0.21  7   7   0.0%
C*01:02:01G/C*07:02:01G 3 (7.1)   2.51  0.86  0.12  7   7   0.0%
C*03:02:01G/C*04:01:01G 1 (2.4)   0.76  0.03  0.52  3   3   0.0%
C*03:02:01G/C*07:01:01G 1 (2.4)   0.42  0.05  0.34  4   4   0.0%
C*03:02:01G/C*07:02:01G 1 (2.4)   0.91  0.05  0.19  2   2   0.0%
C*03:03:01G/C*04:01:01G 1 (2.4)   1.31  1.13  0.48  7   7   0.0%
C*03:03:01G/C*07:02:01G 2 (4.8)   1.57  1.60  0.17 12 12   0.0%
C*03:03:01G/C*14:02:01 3 (7.1)   1.72  0.11  0.03  3   3   0.0%
C*03:03:01G/C*14:03 1 (2.4)  1.09  0.00  0.01  2   2   0.0%
C*03:04:01G/C*04:01:01G 4 (9.5)   1.19  1.70  1.98 12 12   0.0%
C*04:01:01G/C*07:02:01G 1 (2.4)   0.86  3.14  2.54  8   8   0.0%
C*04:01:01G/C*14:02:01 1 (2.4)   0.95  0.21  0.47  4   4   0.0%
C*07:02:01G/C*14:02:01 1 (2.4)   1.14  0.30  0.17  5   5   0.0%
C*08:01:01G/C*15:02:01 1 (2.4)   0.58  0.00  0.00  2   2   0.0%
Subtotal/average 25 (59.5) 25.46 11.54  7.66       6.68        6.68   0.0%
Total/average  42 (100.0) 40.98 19.93 10.75       5.86        4.38 25.2%
SBT, sequence-based typing; HLA, human leukocyte antigen; IMGT, international immunogenetics.
*HLA genotypes were determined based on the IMGT/HLA database release 3.9.0. The occurrence of ambiguous genotyping results and the number of 
ambiguous allele combinations by an SBT assay for an individual may change according to the version of the IMGT/HLA database release.
†Expected genotype frequency was calculated by the Hardy-Weinberg equation with previously reported allele frequencies in Korean and US populations.18,20 
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Unfortunately, considering cost-effectiveness, we includ-
ed limited number of specimens, because HLA SBT is one 
of the most costly and labor-intensive tests in the clinical 
laboratory. Thus, rare HLA alleles could not be analyzed in 
this study. Based on the previously reported HLA allele fre-
quencies in Korean,18 ambiguous genotyping results in this 
study would comprise 50.6%, 14.9%, 41.0%, and 16.9% of 
all possible genotypes with or without ambiguity in Korean 
population for HLA-A, -B, -C, and -DRB1 loci, respectively. 
We only included specimens from Koreans, thus further 
additional labor and cost for the selection and use of proper 
sequencing primer sets, while the AVITA plus assay needs 
additional labor to manipulate more reaction tubes for the 
PCR amplification step than those required in a convention-
al SBT. In the case of HLA-A and -C loci, the AVITA assay 
has an another advantage of producing DNA sequence data 
covering exons 1 to 5 without additional sequencing reac-
tion, and this data can be used to discriminate alleles that 
have different polymorphisms in the regions outside exons 
2 to 4.
Table 6. Reduction of Ambiguous Allele* Combinations with the AVITA Plus Assay for HLA-DRB1 locus
Changes in  
  ambiguity
Most probable type among 
ambiguous allele combinations






























DRB1*01:01:01/DRB1*04:05:01 3 (7.9)   1.26 0.07 0.04 2 1 50.0%
DRB1*01:01:01/DRB1*04:10:01 1 (2.6)   0.12 0.00 0.00 2 1 50.0%
DRB1*01:01:01/DRB1*07:01:01G 2 (5.3)   1.08 2.49 0.49 2 1 50.0%
DRB1*01:01:01/DRB1*09:01:02 1 (2.6)   1.54 0.14 0.16 2 1 50.0%
DRB1*01:01:01/DRB1*12:01:01G 1 (2.6)   0.75 0.24 0.21 2 1 50.0%
DRB1*01:01:01/DRB1*13:02:01 1 (2.6)   1.15 0.73 0.33 4 1 75.0%
DRB1*04:03:01/DRB1*11:01:01G 1 (2.6)   0.17 0.07 0.03 5 1 80.0%
DRB1*04:05:01/DRB1*11:01:01G 1 (2.6)   0.54 0.04 0.15 4 1 75.0%
DRB1*04:05:01/DRB1*12:01:01G 1 (2.6)   0.87 0.01 0.07 3 1 66.7%
DRB1*04:05:01/DRB1*14:03:01 1 (2.6)   0.20 0.00 0.00 2 1 50.0%
DRB1*04:06:01G/DRB1*08:03:02 1 (2.6)   0.76 0.00 0.00 3 1 66.7%
DRB1*04:06:01G/DRB1*14:01:01G 1 (2.6)   0.35 0.00 0.00 2 1 50.0%
DRB1*04:06:01G/DRB1*14:05:01 1 (2.6)   0.39 0.00 0.00 3 1 66.7%
DRB1*04:06:01G/DRB1*15:01:01G 1 (2.6)   0.85 0.01 0.00 2 1 50.0%
DRB1*09:01:02G/DRB1*15:01:01G 1 (2.6)   1.66 0.22 0.16 2 1 50.0%
DRB1*11:01:01G/DRB1*15:01:01G 3 (7.9)   0.51 1.64 0.45 4 1 75.0%
DRB1*12:01:01G/DRB1*15:01:01G 2 (5.3)   0.82 0.38 0.21 3 1 33.3%
DRB1*13:01:01G/DRB1*15:01:01G 2 (5.3)   0.30 1.68 0.30 5 1 80.0%
DRB1*13:02:01/DRB1*15:02:01 2 (5.3)   0.47 0.06 0.02 2 1 50.0%
DRB1*14:03:01/DRB1*15:02:01 1 (2.6)   0.07 0.00 0.00 2 1 50.0%
Subtotal/average 28 (73.7) 13.88 7.79 2.62      2.86      1.00 65.0%
Unchanged
DRB1*03:01:01G/DRB1*14:01:01G 1 (2.6)   0.15 0.00 0.00 5 5   0.0%
DRB1*08:02:01/DRB1*08:03:02 1 (2.6)   0.46 0.00 0.00 4 4   0.0%
DRB1*08:03:02/DRB1*13:02:01 1 (2.6)   1.12 0.66 0.31 3 3   0.0%
DRB1*11:01:01G/DRB1*13:02:01G 1 (2.6)   0.50 0.00 0.00 8 8   0.0%
DRB1*12:01:01G/DRB1*14:01:01G 3 (7.9)   0.34 0.01 0.01 3 3   0.0%
DRB1*12:02:01/DRB1*14:01:01G 1 (2.6)   0.24 0.47 1.10 3 3   0.0%
DRB1*13:01:01G/DRB1*14:01:01G 1 (2.6)   0.13 0.07 0.18 4 4   0.0%
DRB1*13:01:01G/DRB1*14:05:01 1 (2.6)   0.14 0.00 0.01 4 4   0.0%
Subtotal/average 10 (26.3)   3.07 1.21 1.62      4.00      4.00   0.0%
Total/average  38 (100.0) 16.94 8.99 4.24      3.16      1.79 43.3%
SBT, sequence-based typing; HLA, human leukocyte antigen; IMGT, international immunogenetics.
*HLA genotypes were determined based on the IMGT/HLA database release 3.9.0. The occurrence of ambiguous genotyping results and the number of 
ambiguous allele combinations by an SBT assay for an individual may change according to the version of the IMGT/HLA database release.
†Expected genotype frequency was calculated by the Hardy-Weinberg equation with previously reported allele frequencies in Korean and US populations.18,20
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2 and exon 3. Tissue Antigens 1999;53:81-96.
11. Dapprich J, Ferriola D, Magira EE, Kunkel M, Monos D. SNP-
specific extraction of haplotype-resolved targeted genomic re-
gions. Nucleic Acids Res 2008;36:e94.
12. Perng CL, Chang LF, Chien WC, Lee TD, Chang JB. Effectiveness 
and limitations of resolving HLA class I and class II by heterozy-
gous ambiguity resolving primers (HARPs)--a modified technique 
of sequence-based typing (SBT). Clin Biochem 2012;45:1471-8. 
13. Lind C, Ferriola D, Mackiewicz K, Heron S, Rogers M, Slavich L, 
et al. Next-generation sequencing: the solution for high-resolution, 
unambiguous human leukocyte antigen typing. Hum Immunol 
2010;71:1033-42. 
14. Gabriel C, Danzer M, Hackl C, Kopal G, Hufnagl P, Hofer K, et 
al. Rapid high-throughput human leukocyte antigen typing by 
massively parallel pyrosequencing for high-resolution allele iden-
tification. Hum Immunol 2009;70:960-4. 
15. Erlich H. HLA DNA typing: past, present, and future. Tissue Anti-
gens 2012;80:1-11.
16. Gabriel C, Stabentheiner S, Danzer M, Pröll J. What Next? The 
Next Transit from Biology to Diagnostics: Next Generation Se-
quencing for Immunogenetics. Transfus Med Hemother 2011;38: 
308-17. 
17. Shiina T, Suzuki S, Ozaki Y, Taira H, Kikkawa E, Shigenari A, et 
al. Super high resolution for single molecule-sequence-based typ-
ing of classical HLA loci at the 8-digit level using next generation 
sequencers. Tissue Antigens 2012;80:305-16. 
18. Chung HY, Yoon JA, Han BY, Song EY, Park MH. [Allelic and 
haplotypic diversity of HLA-A, -B, -C, and -DRB1 genes in Ko-
reans defined by high-resolution DNA typing]. Korean J Lab Med 
2010;30:685-96. 
19. Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity 
of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean popu-
lation. Tissue Antigens 2005;65:437-47.
20. Maiers M, Gragert L, Klitz W. High-resolution HLA alleles and 
haplotypes in the United States population. Hum Immunol 2007; 
68:779-88. 
study for other ethnic groups would be needed to evaluate 
the usefulness of the AVITA assay in resolving ambiguity 
for HLA alleles uncommon in Korean. Actually, ambiguous 
HLA allele combinations analyzed in our study showed 
lower expected genotype frequencies for populations other 
than Korean (Table 3-6). We used different DNA sequenc-
ing platforms and SBT analysis softwares for the respective 
SBT assays. The quality of sequenced results and difference 
in the base calling processes for the respective instruments 
and platforms may affect the interpreted results. However, 
the most probable HLA-A, -B, -C, and -DRB1 genotypes for 
the respective specimens, determined by the two assays, 
were all concordant with each other. Thus, errors which 
could occur by the different platforms in this study would 
not significantly affect the results.
In summary, the AVITA plus HLA SBT test reduced the 
numbers of ambiguous cases with high-resolution HLA typ-
ing, particularly for the HLA-A, -B, and -DRB1 loci. In 
many cases, this assay did not require additional tests to re-
solve the ambiguity compared to the conventional SBT as-
say. Therefore, the AVITA plus HLA SBT assay would be 
useful for reducing ambiguity in the interpretation of HLA 
typing in clinical laboratories for transplantation.
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